HomeWebcastParagraph IV Patent Protection and Litigation: Addressing the Complex Challenges in 2019 and Beyond
Online CLE Paragraph IV CLE

Paragraph IV Patent Protection and Litigation: Addressing the Complex Challenges in 2019 and Beyond

Live Webcast Date: Tuesday, September 17, 2019 from 3:00 pm to 5:00 pm (ET)
CLE Intellectual Property LawLive Webcast
Listen Live/On-Demand
Add to Calendar 09/17/2019 2:00 pm 09/17/2019 5:00 pm America/New_York The Knowledge Group Webinar: Paragraph IV Patent Protection and Litigation: Addressing the Complex Challenges in 2019 and Beyond The event starts in an hour. If you have not registered, please go to the link below to sign up today.https://www.theknowledgegroup.org/checkout/?add-to-cart=136228\r\n Protecting pharmaceutical patents in today’s business landscape is even made more challenging by the growing number of threats and risks. One of the crucial weak spots for drug companies aiming to guard their patents is the Abbreviated New Drug Application (ANDA) process, particularly Paragraph IV (PIV) certification. It is already becoming common for brand companies to receive a PIV challenge from a generic company. \n \nThe increasing PIV filings require both patent holders and challengers to be equipped with up-to-date knowledge of addressing complex challenges surrounding patent protection and PIV disputes. \n \nIn this LIVE Webcast, a seasoned panel of thought leaders and professionals brought together by The Knowledge Group will provide insights on how to manage the complex challenges that both brand name and generic drug manufacturers face. The speakers will present the recent patent infringement cases that have significant implications on the current legal setting. They will also offer the best practices in protecting patents and litigating PIV effectively. \n \nThis LIVE Webcast will discuss the following key provisions: \n \n \n Paragraph IV Filings – Statistics \n Patent Protection – Recent Trends \n Notable Patent Infringement Cases \n Complex Challenges \n Best Patent Protection Practices \n Practical Litigation Tips \n Outlook \n https://www.theknowledgegroup.org/webcasts/paragraph-iv-patent-protection-and-litigation/

Online CLE Paragraph IV

Join us for this Knowledge Group Online CLE Paragraph IV Webinar. Protecting pharmaceutical patents in today’s business landscape is even made more challenging by the growing number of threats and risks. One of the crucial weak spots for drug companies aiming to guard their patents is the Abbreviated New Drug Application (ANDA) process, particularly Paragraph IV (PIV) certification. It is already becoming common for brand companies to receive a PIV challenge from a generic company.

The increasing PIV filings require both patent holders and challengers to be equipped with up-to-date knowledge of addressing complex challenges surrounding patent protection and PIV disputes.

In this LIVE Webcast, a seasoned panel of thought leaders and professionals brought together by The Knowledge Group will provide insights on how to manage the complex challenges that both brand name and generic drug manufacturers face. The speakers will present the recent patent infringement cases that have significant implications on the current legal setting. They will also offer the best practices in protecting patents and litigating PIV effectively.

This LIVE Webcast will discuss the following key provisions:

  • Paragraph IV Filings – Statistics
  • Patent Protection – Recent Trends
  • Notable Patent Infringement Cases
  • Complex Challenges
  • Best Patent Protection Practices
  • Practical Litigation Tips
  • Outlook

Agenda

Pablo Hendler, Partner
Jones Day

James Li, Attorney
O'Melveny & Myers LLP

Who Should Attend

  • Patent Lawyers and Consultants
  • Patent Agents
  • Patent Portfolio Managers
  • In-house Counsel
  • Top Level Management
  • Pharmaceutical Companies

Online CLE Paragraph IV

Pablo Hendler, Partner
Jones Day

James Li, Attorney
O'Melveny & Myers LLP

Online CLE Paragraph IV

Online CLE Paragraph IV

Pablo HendlerPartnerJones Day

Pablo Hendler has counseled clients for nearly 25 years in intellectual property matters. Focusing his practice on life science patent litigation, he is well-equipped to counsel clients in pharmaceutical, biotechnology, and medical device litigation.  Specifically, Pablo has served as lead counsel, in both the Federal Courts and the Patent Trial and Appeal Board.  His extensive litigation experience, and his background as a researcher and inventor, has served him well in counseling clients on how to successfully cross the intersection of FDA and patent law.

Pablo's clients have consistently praised him as an "excellent lawyer" and for his "sterling" work in ANDA litigations. They are comforted by his "seen-and-done-it-all experience" who “blends deep patent law and regulatory knowledge.”

Pablo has written and spoken on a broad range of patent-related topics, particularly in the area of Hatch Waxman litigation.

Online CLE Paragraph IV

James LiAttorneyO'Melveny & Myers LLP

James Yi Li is a patent litigator at O’Melveny & Myers LLP where he focuses his practice on life sciences matters, including cases brought under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.  James received his law degree from Harvard Law School, where he served as the Submissions Editor for the Harvard Journal of Law & Technology.  He has a Masters Degree in Pharmaceutical Engineering and a B.S.E. in Biomedical Engineering, both from the University of Michigan, where he graduated summa cum laude. 

Online CLE Paragraph IV

Course Level:
   Intermediate

Advance Preparation:
   Print and review course materials

Method Of Presentation:
   Live Webcast

Prerequisite:
   General knowledge of patent laws

Course Code:
   148353

NY Category of CLE Credit:
   Areas of Professional Practice

Total Credits:
    2.0 CLE

No Access

You are not logged in. Please or register to the event to gain access to the materials and login instructions.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.

Website: https://www.omm.com/

Pablo Hendler has counseled clients for nearly 25 years in intellectual property matters. Focusing his practice on life science patent litigation, he is well-equipped to counsel clients in pharmaceutical, biotechnology, and medical device litigation.  Specifically, Pablo has served as lead counsel, in both the Federal Courts and the Patent Trial and Appeal Board.  His extensive litigation experience, and his background as a researcher and inventor, has served him well in counseling clients on how to successfully cross the intersection of FDA and patent law.

Pablo's clients have consistently praised him as an "excellent lawyer" and for his "sterling" work in ANDA litigations. They are comforted by his "seen-and-done-it-all experience" who “blends deep patent law and regulatory knowledge.”

Pablo has written and spoken on a broad range of patent-related topics, particularly in the area of Hatch Waxman litigation.

James Yi Li is a patent litigator at O’Melveny & Myers LLP where he focuses his practice on life sciences matters, including cases brought under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.  James received his law degree from Harvard Law School, where he served as the Submissions Editor for the Harvard Journal of Law & Technology.  He has a Masters Degree in Pharmaceutical Engineering and a B.S.E. in Biomedical Engineering, both from the University of Michigan, where he graduated summa cum laude. 

Ultimate Value Annual Program

Bring a colleague for only $149, a savings of $50 per additional attendee.

  • Unlimited Access to Live & Recorded Webcasts
  • Instant Access to Course Materials
  • And More!

$199